AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9786602
Drug: All antihypertensive
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All antihypertensive agents
Trial: 7665814
Drug: Current medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current medical therapy for severe ulcerative colitis
Trial: 7665814
Drug: Current medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current medical therapy for severe Crohn's colitis
Trial: 29164377
Drug: 3.25 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.25 mg/day DHEA
Trial: 29164377
Drug: 6.5 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.5 mg/day DHEA
Trial: 25194884
Drug: beclomethasone/formoterol (100/6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beclomethasone/formoterol (100/6 μg) bid
Trial: 25194884
Drug: budesonide/formoterol (160/4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: budesonide/formoterol (160/4.5 μg) bid
Trial: 17581531
Drug: sustained‐release bupropion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sustained‐release bupropion 150 mg twice daily
Trial: 17121524
Drug: l-thyroxine (low-TSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-thyroxine (low-TSH group, 13 patients)
Trial: 17121524
Drug: l-thyroxine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-thyroxine plus placebo (euthyroidism group, 12 patients)
Trial: 10807468
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g vitamin C (single dose)
Trial: 10807468
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g vitamin C daily for 8 weeks
Trial: 8632572
Drug: 10.8 mg
RxNorm normalized name: goserelin 10.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.8 mg goserelin depot, administered every 12 weeks
Trial: 8632572
Drug: 3.6 mg
RxNorm normalized name: menthol 3.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 mg goserelin depot, administered every 4 weeks
Trial: 8632572
Drug: 10.8 mg
RxNorm normalized name: goserelin 10.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.8 mg goserelin depot
Trial: 6402355
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg cellulose bound nitroglycerin
Trial: 6402355
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg cellulose bound nitroglycerin
Trial: 30633722
Drug: Belatacept infusions
RxNorm normalized name: Belatacept
DrugBank: Belatacept (DB06681)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Belatacept infusions
Trial: 19561259
Drug: Drip infusion
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drip infusion for VCUG
Trial: 14647133
Drug: Sustained-release oxycodone
RxNorm normalized name: oxycodone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release oxycodone (CRO)
Trial: 14647133
Drug: Sustained-release morphine
RxNorm normalized name: morphine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release morphine (CRM)
Trial: 14647133
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of morphine and oxycodone
Trial: 10756544
Drug: Alginate gel
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginate gel beads prepared with low molecular size alginate
Trial: 10756544
Drug: Alginate gel
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginate gel beads (general)
Trial: 10756544
Drug: Commercial sustained-release
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial sustained-release tablet (Carvisken)
Trial: 8930425
Drug: Ceftibuten oral
RxNorm normalized name: ceftibuten Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftibuten oral suspension 9 mg/kg once daily (maximum dose, 400 mg/d) for 10 days
Trial: 8930425
Drug: Cefprozil oral
RxNorm normalized name: cefprozil Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefprozil oral suspension 15 mg/kg twice daily (maximum dose, 1000 mg/d) for 10 days
Trial: 1473854
Drug: Modified Release
RxNorm normalized name: MODIFIED RELEASE CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Release (MR) formulation of diltiazem (60 mg)
Trial: 1473854
Drug: Modified Release
RxNorm normalized name: MODIFIED RELEASE CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Release (MR) formulation of diltiazem
Trial: 1473854
Drug: Immediate Release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate Release (IR) formulation of diltiazem (60 mg)
Trial: 2865156
Drug: Beta-adrenoceptor blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenoceptor blocker (propranolol)
Trial: 2865156
Drug: Combined alpha-
RxNorm normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined alpha- and beta-adrenoceptor blocker (labetalol)
Trial: 27630373
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg or 1.0 mg administered at tumor localization and every 2 months for 24 months
Trial: 19068079
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg delta(9)-THC
Trial: 19068079
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg delta(9)-THC
Trial: 19068079
Drug: delta(9)-THC with
RxNorm normalized name: .DELTA.1-THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: delta(9)-THC with SR141716A (CB(1) receptor antagonist)
Trial: 27175657
Drug: EALM therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EALM therapy (esomeprazole 40 mg bid and amoxicillin 1 g bid for 5 days, followed by esomeprazole 40 mg bid, levofloxacin 500 mg qd, and metronidazole 500 mg tid, for 5 days)
Trial: 27175657
Drug: 10-day EAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day EAL therapy (levofloxacin 500 mg qd, amoxicillin 1 g bid, and esomeprazole 40 mg bid)
Trial: 20840223
Drug: Supervised implementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised implementation of the oral health care guideline
Trial: 18596969
Drug: HPC containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPC containing 0.03% FGF-2 (Group L)
Trial: 16858953
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus dipyridamole (aspirin 300 mg/d + dipyridamole 75 mg thrice a day)
Trial: 16858953
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (300 mg/d)
Trial: 10638394
Drug: 5-mg oral
RxNorm normalized name: Augmentin 875-mg Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mg oral doses of amlodipine (reference formulation)
Trial: 10638394
Drug: 5-mg oral
RxNorm normalized name: Augmentin 875-mg Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mg oral doses of amlodipine (test formulation)
Trial: 1788636
Drug: Ultra-high streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-high streptokinase therapy
Trial: 1788636
Drug: Conventional streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional streptokinase dosage
Trial: 7270985
Drug: Weekly injections
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly injections of ragweed antigen
Trial: 7270985
Drug: Monthly injections
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly injections of ragweed antigen
Trial: 30672255
Drug: Herb-separated moxibustion
RxNorm normalized name: serrated swimming crab, cooked preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herb-separated moxibustion combined with sulfasalazine enteric-coated tablets
Trial: 30672255
Drug: Conventional moxibustion
RxNorm normalized name: BUTYLENE GLYCOL 0.2 g in 1 g CUTANEOUS TAPE [ShiZhenTaiYiTang Moxibustion Patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional moxibustion combined with sulfasalazine enteric-coated tablets
Trial: 24112528
Drug: Blood (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood (1 mL)
Trial: 21044117
Drug: Aldosterone levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone levels before adrenalectomy (235.0 ± 51.1 pg/ml)
Trial: 16547688
Drug: Calcitriol treatment
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcitriol treatment (1 microg/day for 7 days)
Trial: 12968960
Drug: Fibrin glue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin glue (4 ml) applied to wound surfaces and under the flap
Trial: 11068889
Drug: Child-alone cognitive-behavioral
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child-alone cognitive-behavioral treatment
Trial: 11068889
Drug: Family cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family cognitive-behavioral treatment
Trial: 7731155
Drug: Nonionic contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonionic contrast agent (iohexol)
Trial: 3882619
Drug: Ionic contrast
RxNorm normalized name: IONIC CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ionic contrast agent (sodium methylglucamine diatrizoate)
Trial: 30994776
Drug: In‐office bleaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In‐office bleaching with 35% HP and one application of placebo gel (20 minutes), followed by at‐home bleaching with 10% CP (2 hours/day for 16 days)
Trial: 26990892
Drug: Single high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high-dose melphalan followed by autologous transplantation (HDM/ASCT)
Trial: 26990892
Drug: Tandem high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandem high-dose melphalan followed by autologous transplantation (HDM/ASCT)
Trial: 23519436
Drug: Dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5 µg kg‐1
Trial: 23519436
Drug: Dexmedetomidine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1.0 µg kg‐1
Trial: 18387931
Drug: Rimonabant (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimonabant (20 mg daily)
Trial: 11679528
Drug: GnRH analogue
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH analogue (leuprolide acetate depot, 3.75 mg, monthly i.m. injections for 3 months)
Trial: 7933233
Drug: Expectant management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectant management (no treatment)
Trial: 8169405
Drug: cold‐recombinant, trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cold‐recombinant, trivalent influenza vaccine
Trial: 3127050
Drug: Deprenyl 5
RxNorm normalized name: (11C)L-deprenyl-D2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deprenyl 5 mg b.i.d.
Trial: 23517885
Drug: Pramipexole (0.375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole (0.375 mg/day titrated to 2.25 mg/day)
Trial: 23517885
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pramipexole and escitalopram
Trial: 21803570
Drug: Chemotherapy (CAIRO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CAIRO study)
Trial: 21803570
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus targeted therapy (CAIRO2 study)
Trial: 11371411
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (control; usual treatment)
Trial: 25214548
Drug: Concurrent SLN/RLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent SLN/RLN injury group (n = 8)
Trial: 22759326
Drug: Empirical concomitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical concomitant therapy (PPI, amoxicillin 1 g, clarithromycin 500 mg, metronidazole 500 mg; all drugs b.i.d.)
Trial: 22759326
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy for clarithromycin-susceptible H. pylori
Trial: 22759326
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy for clarithromycin-resistant strains
Trial: 18555939
Drug: Aminaftone 75
RxNorm normalized name: Aminaftone
DrugBank: Aminaphthone (DB13039)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminaftone 75 mg TID for 12 weeks
Trial: 12449290
Drug: Commercial antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial antioxidant supplement (dried fruit and vegetable extracts, fortified with antioxidants, gummy-type candy), taken in 2 doses per day for 21 days
Trial: 12449290
Drug: Placebo, taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, taken in 2 doses per day for 21 days
Trial: 10366112
Drug: High-dose D-penicillamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose D-penicillamine (750-1,000 mg/day)
Trial: 10366112
Drug: Low-dose D-penicillamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose D-penicillamine (125 mg every other day)
Trial: 7025719
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose cisplatin (120 mg/m2) with vindesine
Trial: 7025719
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cisplatin (60 mg/m2) with vindesine
Trial: 31688572
Drug: E2 vaginal
RxNorm normalized name: Prostin E2 Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 vaginal inserts (4, 10, or 25 μg)
Trial: 28903965
Drug: Enteric-coated mycophenolate
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated mycophenolate sodium (EC-MPS) plus low-dose corticosteroids
Trial: 28903965
Drug: Low-dose corticosteroids
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose corticosteroids (monotherapy)
Trial: 17670916
Drug: Glucose solution
RxNorm normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose solution (75 g in 300 ml water)
Trial: 22240615
Drug: Ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5 mg kg(‐1)
Trial: 11893258
Drug: Cellophane patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellophane patch
Trial: 11893258
Drug: Gentamicin ointment
RxNorm normalized name: gentamicin Ophthalmic Ointment
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gentamicin ointment seal
Trial: 2220138
Drug: New trocar-cannula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New trocar-cannula combination (10 French)
Trial: 371561
Drug: Diflunisal (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal (250 mg b.i.d.)
Trial: 26482247
Drug: Dialysate sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate sodium reduced from 138mmol/l to 136mmol/l
Trial: 26482247
Drug: Dialysate sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate sodium remained at 138mmol/l
Trial: 23204096
Drug: 35 percent
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 35 percent calcium-free (CF) hydrogen peroxide gel
Trial: 23204096
Drug: 35 percent
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 35 percent calcium-containing (CC) hydrogen peroxide gel
Trial: 11214781
Drug: Glibenclamide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (2.5 mg)
Trial: 11214781
Drug: Glipizide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizide (2.5 mg)
Trial: 8878758
Drug: Trimethoprim/sulfamethoxazole treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim/sulfamethoxazole treatment
Trial: 30933599
Drug: Weekly vouchers
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly vouchers
Trial: 30933599
Drug: Monthly vouchers
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly vouchers
Trial: 25857366
Drug: Silymarin 420
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin 420 mg daily in three divided doses starting 24‐48 h before cisplatin infusion and continuing through three 21‐day cisplatin chemotherapy courses
Trial: 25110226
Drug: Low-glucose PD
RxNorm normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal PD-2/2.5]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-glucose PD regimen (dextrose-based PD solution plus icodextrin and amino acids)
Trial: 25110226
Drug: Conventional PD
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional PD regimen (dextrose PD solutions)
Trial: 19008494
Drug: Low-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat meal (approximately 530 kcal; 100 g of carbohydrate, 1 g of fat, and 30 g of protein)
Trial: 19008494
Drug: Control meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control meal (approximately 800 kcal; 100 g of carbohydrate, 31 g of fat, and 30 g of protein)
Trial: 19008494
Drug: Low-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat meal plus lipid infusion (same meal as low-fat meal, total energy 800 kcal, with approximately 30 g fat via intravenous lipid infusion)
Trial: 17595937
Drug: Caudal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal ketamine 0.5 mg/kg diluted with 0.9% saline
Trial: 17595937
Drug: Caudal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal ketamine mixed with 0.125% bupivacaine 1 ml/kg
Trial: 17595937
Drug: Plain 0.125%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain 0.125% bupivacaine 1 ml/kg
Trial: 11588451
Drug: Gastric feeding
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric feeding with erythromycin (200 mg iv every 8 hrs)
Trial: 9661589
Drug: Estradiol levels
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol levels from 10-25 pg/mL
Trial: 9661589
Drug: Estradiol levels
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol levels below 5 pg/mL
Trial: 9661589
Drug: Estradiol levels
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol levels exceeding 5 pg/mL
Trial: 8005183
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg iv infusion
Trial: 8005183
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral solution
Trial: 8005183
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg standard tablet
Trial: 8005183
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg slow release formulation
Trial: 2523957
Drug: GR 38032F,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR 38032F, 0.18 mg/kg, every six or every eight hours for three doses, beginning 30 minutes before cisplatin
Trial: 596252
Drug: Intestinal sterilization
RxNorm normalized name: pork intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intestinal sterilization with systemic antibiotics
Trial: 19017893
Drug: Supervised asthma
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supervised asthma therapy
Trial: 16462710
Drug: Acarbose therapy
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose therapy
Trial: 11455971
Drug: Regimen A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A: 12 intensive parenteral treatments of intermediate dose (1 g/m2 each) methotrexate (MTX) and mercaptopurine (MP) over 24 weeks.
Trial: 11455971
Drug: Regimen B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B: 12 intensive courses of alternating myelosuppressive drug combinations over 30 weeks, including MTX/MP, teniposide (VM-26)/cytosine arabinoside (AC), and VCR/PDN/DNR/AC/ASP.
Trial: 9724685
Drug: G‐6‐PD‐deficient neonates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐6‐PD‐deficient neonates with hyperbilirubinemia
Trial: 9724685
Drug: G‐6‐PD‐deficient neonates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐6‐PD‐deficient neonates without hyperbilirubinemia
Trial: 1378106
Drug: Piroximone (0.5‐mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroximone (0.5‐mg/kg bolus in 30 min and then 3‐6 micrograms/kg/min)
Trial: 1378106
Drug: Enoximone (1‐mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (1‐mg/kg bolus and then 4‐20 micrograms/kg/min)